ADHD therapeutics market led by Shire Pharmaceuticals

Press Release   •   Jun 10, 2013 09:59 BST

The Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market has been forecast to show strong growth in Spain and Japan over the next five years, with compound annual growth rates (CAGRs) of 8% and 15% respectively.

However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260 million by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.

ADHD is a psychiatric disorder or neurobehavioral disorder characterised by significant difficulties either of inattention or hyperactivity and impulsiveness or a combination of the two.

ADHD, a common neurodevelopmental psychiatric disorder, affects an estimated 5% of the worldwide children in the age group of 5-17 years.

Genetics play a major role in its propagation, with almost three-fourth of the diagnosed patients having some history of ADHD in their families. Currently, stimulant medication used in conjunction with behavioural interventions is considered the best treatment option for ADHD patients.

ADHD management usually involves some combination of medications, behaviour therapy, lifestyle changes, and counselling. Medications are only recommended as a first-line treatment option in children who have severe symptoms.

Medication therapy can also be considered for those with moderate ADHD symptoms who either refuse psychotherapeutic options or else fail to respond to psychotherapeutic input.

Existing ADHD drugs are only successful in fulfilling the therapeutic needs of ADHD treatment, with issues relating to complete cure, efficacy and safety remaining unresolved. The existing drugs work by reducing the remission rates, increasing the disorder's relapse rates, and treating the symptoms rather than the disorder itself.

As multiple ADHD drugs such as Adderall XR (amphetamine and dextroamphetamine), Daytrana (methylphenidate), Intuniv, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to lose their patents, new treatment options are required to prevent declining market revenue. However, uncertain disease epidemiology is making development difficult.

The ADHD pipeline features some promising molecules, but many are still in early stages of development.

Shire Plc, Johnson & Johnson and Eli Lilly & Company represent the leading players within the global ADHD therapeutics market. Shire Pharmaceuticals is the largest player with its strong portfolio of drugs including Adderall XR, Vyvanse, Daytrana and Intuniv.

For more information on the ADHD therapeutics market, see the latest research: ADHD Therapeutics Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.